Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
Category: #health  By Pankaj Singh  Date: 2020-09-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharmaceutical company that develops and commercializes life-changing pharmaceutical products that address the serious medical needs of Greater China and other Asian regions. The study met its main objective, showing that the combined treatment of Cefepime-Taniborbactam was safe and well endured among healthy Chinese volunteers with important pharmacokinetics constraints representing no detectable signal of ethnic differences.

Everest Medicine’s Chief Medical Officer for Infectious Diseases, Sunny Zhu confirmed that China is still encountering the difficulties of high infection rates caused due to MDR pathogens. Cefepime with novel β-lactamase inhibitor mechanism of action of Taniborbactam, is an antibiotic that is the portion of the present and recognized standards of care, has the potential of treating a wide range of MDR pathogens, specifically the infections caused due to carbapenem-resistant Gram-negative pathogens, helping to resolve the unique issue in the region. They are looking forward to enhancing the clinical development of Cefepime-Taniborbactam in this key disease region as they put efforts to bring potentially the best therapy for patients worldwide.

The MD, Ph.D., CEO of Everest Medicines, Kerry Blanchard stated that a sense of urgency is emphasized in their efforts due to the ongoing events, to address severe infectious diseases. He thanked that patients and their families along with the healthcare providers for their dedication to helping them bring advanced antibiotics to all the patients in need.

Everest Medicines is also assessing Cefepime-Taniborbactam in a global key Phase 3 clinical trial to treat complex urinary tract infection with the support of Venatorx Pharmaceuticals. Under a unique licensing contract with Venatorx Pharmaceuticals, the biopharmaceutical company has the privilege to produce and commercialize Cefepime-Taniborbactamin in Hong Kong, Mainland China, South Korea, Macau, Indonesia, Taiwan, Philippines, Thailand, Malaysia, Vietnam, and Singapore.

 

Source: https://www.globenewswire.com/news-release/2020/09/15/2093360/0/en/Everest-Medicines-Announces-Top-line-Results-from-Phase-1-Clinical-Trial-of-Taniborbactam-in-Combination-with-Cefepime-in-China.html

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

GENFIT & LabCorp Come Together to Develop a Diagnostic Test for NASH
GENFIT & LabCorp Come Together to Develop a Diagnostic Test for NASH
By Pankaj Singh

GENFIT, a biopharmaceutical company committed to improving the lives of patients suffering from liver and metabolic diseases, and LabCorp®, a leading life sciences enterprise focuses on guiding patient care decisio...

RADLogics obtains FDA's approval for AI-based chest X-Ray App
RADLogics obtains FDA's approval for AI-based chest X-Ray App
By Pankaj Singh

RADLogics Inc., a healthcare software company developing AI-powered solutions has reportedly received 510(k) clearance from the US FDA (Food and Drug Administration) for its latest AI-Powered chest X-ray pneumothorax a...

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...